MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
VSTM stock logo

VSTM

Verastem, Inc.

$5.63
0.08
 (1.44%)
[ms_data_label text=’Delayed data’]
Exchange:  NASDAQ
Market Cap:  390.237M
Shares Outstanding:  12.777M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Daniel W. Paterson
Full Time Employees:  78
Address: 
117 Kendrick Street
Needham
MA
2494
US
Website:  https://www.verastem.com
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer’s inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen’s KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/08/08 — Q2 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue010,00030,914
Gross Profit010,00025,616
EBITDA-83,166-125,864-170,129
Operating Income-92,084-114,956-170,129
Net Income-87,367-130,637-209,471

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets149,718101,538246,442
Total Liabilities92,344130,431189,245
Total Stockholders Equity57,374-28,89357,197
Total Debt41,55742,25476,865
Cash and Cash Equivalents78,83588,818204,990

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-86,460-104,771-137,509
Capital Expenditure7-280
Free Cash Flow-86,460-104,799-137,509
Net Income-87,367-130,637-209,471
Net Change in Cash3,2879,983116,172

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)540,120.686Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)690,279.001Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)597,302.667Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-414,167.400Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-324,072.411Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-358,381.600Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)58,963.939Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)80,973.705Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)67,345.477Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)3,170,928.642Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)4,052,474.774Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)3,506,631.358Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0.970Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)1.170Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.850Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)6Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)2Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
0  ?P/S
 (TTM)
: 
14.75
?Net Income
 (TTM)
: 
-87367000  ?P/E
 (TTM)
: 
-2.62
?Enterprise Value
 (TTM)
: 
338.264M  ?EV/FCF
 (TTM)
: 
-2.46
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-18.5  ?ROIC
 (TTM)
: 
-0.95
?Net Debt
 (TTM)
: 
-71986000  ?Debt/Equity
 (TTM)
: 
1.52
?P/B
 (TTM)
: 
9.59  ?Current Ratio
 (TTM)
: 
3.09

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate VSTM Intrinsic Value

Common questions about VSTM valuation

Is Verastem, Inc. (VSTM) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Verastem, Inc. (VSTM) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is VSTM a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether VSTM trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is VSTM’s P/E ratio?

You can see VSTM’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for VSTM?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is VSTM a good long-term investment?

Whether VSTM fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

VSTM

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

1.44
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low: 4.01   Year High: 11.25
Price Avg 50: 5.91   Price Avg 200: 7.38
Volume: 1.838M   Average Volume: 1.91M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Verastem, Inc. (NASDAQ:VSTM) Receives Average Rating of “Moderate Buy” from Analysts
24-04-2026 02:31
Verastem, Inc. (NASDAQ:VSTM) Receives Average Rating of “Moderate Buy” from Analysts
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12-01-2026 16:01
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual
17-03-2026 16:44
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual
What Makes Verastem (VSTM) a New Buy Stock
17-02-2026 13:01
What Makes Verastem (VSTM) a New Buy Stock
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results
05-02-2026 12:45
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC
30-12-2025 15:37
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read